These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 19210163)
1. A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. Karron RA; Callahan K; Luke C; Thumar B; McAuliffe J; Schappell E; Joseph T; Coelingh K; Jin H; Kemble G; Murphy BR; Subbarao K J Infect Dis; 2009 Mar; 199(5):711-6. PubMed ID: 19210163 [TBL] [Abstract][Full Text] [Related]
2. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. Talaat KR; Karron RA; Callahan KA; Luke CJ; DiLorenzo SC; Chen GL; Lamirande EW; Jin H; Coelingh KL; Murphy BR; Kemble G; Subbarao K Vaccine; 2009 Jun; 27(28):3744-53. PubMed ID: 19464558 [TBL] [Abstract][Full Text] [Related]
3. An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults. Talaat KR; Karron RA; Liang PH; McMahon BA; Luke CJ; Thumar B; Chen GL; Min JY; Lamirande EW; Jin H; Coelingh KL; Kemble GW; Subbarao K Influenza Other Respir Viruses; 2013 Jan; 7(1):66-73. PubMed ID: 22417012 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Karron RA; Talaat K; Luke C; Callahan K; Thumar B; Dilorenzo S; McAuliffe J; Schappell E; Suguitan A; Mills K; Chen G; Lamirande E; Coelingh K; Jin H; Murphy BR; Kemble G; Subbarao K Vaccine; 2009 Aug; 27(36):4953-60. PubMed ID: 19540952 [TBL] [Abstract][Full Text] [Related]
5. Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults. Aichinger G; Grohmann-Izay B; van der Velden MV; Fritsch S; Koska M; Portsmouth D; Hart MK; El-Amin W; Kistner O; Barrett PN Clin Vaccine Immunol; 2015 Jan; 22(1):46-55. PubMed ID: 25355797 [TBL] [Abstract][Full Text] [Related]
6. Cross- immunity of a H9N2 live attenuated influenza vaccine against H5N2 highly pathogenic avian influenza virus in chickens. Wang M; Wei Y; Pu J; Bing G; Sun Y; Sun H; Wei F; Liu J Vet Microbiol; 2018 Jul; 220():57-66. PubMed ID: 29885802 [TBL] [Abstract][Full Text] [Related]
7. An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults. Talaat KR; Karron RA; Luke CJ; Thumar B; McMahon BA; Chen GL; Lamirande EW; Jin H; Coelingh KL; Kemble G; Subbarao K Vaccine; 2011 Apr; 29(17):3144-8. PubMed ID: 21377509 [TBL] [Abstract][Full Text] [Related]
8. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy. Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631 [TBL] [Abstract][Full Text] [Related]
9. Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study. Rudenko L; Kiseleva I; Stukova M; Erofeeva M; Naykhin A; Donina S; Larionova N; Pisareva M; Krivitskaya V; Flores J; Vaccine; 2015 Sep; 33(39):5110-7. PubMed ID: 26296497 [TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Atmar RL; Keitel WA; Patel SM; Katz JM; She D; El Sahly H; Pompey J; Cate TR; Couch RB Clin Infect Dis; 2006 Nov; 43(9):1135-42. PubMed ID: 17029131 [TBL] [Abstract][Full Text] [Related]
11. Development of a dual-protective live attenuated vaccine against H5N1 and H9N2 avian influenza viruses by modifying the NS1 gene. Choi EH; Song MS; Park SJ; Pascua PN; Baek YH; Kwon HI; Kim EH; Kim S; Jang HK; Poo H; Kim CJ; Choi YK Arch Virol; 2015 Jul; 160(7):1729-40. PubMed ID: 25959557 [TBL] [Abstract][Full Text] [Related]
16. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Ambrose CS; Luke C; Coelingh K Influenza Other Respir Viruses; 2008 Nov; 2(6):193-202. PubMed ID: 19453395 [TBL] [Abstract][Full Text] [Related]
17. Live attenuated vaccines for pandemic influenza. Chen GL; Subbarao K Curr Top Microbiol Immunol; 2009; 333():109-32. PubMed ID: 19768402 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine. Atmar RL; Keitel WA; Quarles JM; Cate TR; Patel SM; Nino D; Wells J; Arden N; Guo K; Hill H; Couch RB Vaccine; 2011 Oct; 29(45):8066-72. PubMed ID: 21864622 [TBL] [Abstract][Full Text] [Related]
19. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737 [TBL] [Abstract][Full Text] [Related]
20. Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses. Kiseleva I; Dubrovina I; Fedorova E; Larionova N; Isakova-Sivak I; Bazhenova E; Pisareva M; Kuznetsova V; Flores J; Rudenko L Vaccine; 2015 Dec; 33(49):7008-14. PubMed ID: 26432909 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]